Amgen Creates New VP Post For Reimbursement & Payment Policy
This article was originally published in The Pink Sheet Daily
Executive Summary
Joshua Ofman, MD, will work with reimbursement stakeholders, including CMS and MedPac, as the Medicare drug benefit is implemented. He joined Amgen in 2003 as senior director of U.S. medical affairs.
|
Amgen has named Joshua Ofman, MD, to the newly created position of VP-reimbursement and payment policy. Ofman will work with reimbursement stakeholders, particularly government agencies such as the Centers for Medicare & Medicaid Services and the Medicare Payment Advisory Commission, as the Medicare Rx drug benefit is implemented. He also will assume responsibility for integrating reimbursement needs into the product development and commercialization process. Ofman has been senior director-U.S. medical affairs since joining Amgen in 2003. Following the addition of Senior VP-Global Governmental Affairs David Beier in December 2003, Amgen has been strengthening its government affairs staff. VP-Government Affairs Rodger Currie joined Amgen in May. Currie previously was chief lobbyist for the Pharmaceutical Research & Manufacturers of America (1 (Also see "PhRMA Chief Lobbyist Currie Will Head Amgen D.C. Office" - Pink Sheet, 30 Mar, 2004.)). Two more former PhRMA lobbyists, Mara Guarducci and Scott Olsen, joined Amgen as government affairs directors (2 (Also see "Amgen Adds Two More PhRMA Lobbyists To D.C. Office" - Pink Sheet, 13 Apr, 2004.)). - Benjamin Lum |